Dendritic cell–based vaccines (KSD-101) against EBV-associated lymphoproliferative diseases: Results from an ongoing phase I clinical study.

Chunrui Li, Di Wang, Atsuhiko Hasegawa, Huining Liu, Peiling Zhang, Yuhan Bao, Ning An, Mei Huang, Yi Xiao, Donghua Zhang, Miao Zheng, Wei Huang, Lijun JiangJournal of Clinical Oncology 2025 · DOI

Abstract

e14515 Background: The Epstein–Barr Virus (EBV) infects over 95% of the global population. The WHO has definitively identified EBV as the first human tumor-associated virus, thereby underscoring the necessity for novel therapeutic options. KSD-101, a First-in-class autologous dendritic cell (DC) vaccine which is loaded with the EBV-related antigen, is specifically tailored to target EBV-associated lymphoproliferative diseases (EBV-LPDs). Methods: Patients (pts) with EBV-LPDs and have not respond to or relapsed after standard treatment will be enrolled. Pts will receive monotherapy with KSD-101 via subcutaneous injection once every 2 weeks for 3-5 doses, without requiring pre-treatment lymphodepletion. The study used a 3+3 dose-escalation design, aiming primarily to assess tolerability, safety, dose-limiting toxicities (DLT) and maximum tolerated dose (MTD), with secondary objective to explore clinical efficacy and immune responses. Results: Between January 16, 2023, and May 21, 2024, 11 pts were ultimately enrolled and treated with KSD-101. In the escalation phase, 3 pts received 5.0 × 10 6 cells/dose and 2 pts received 7.5 × 10 6 cells/dose. Based on the safety, preliminary efficacy, and feasibility assessment, we decided to cancel the third dose group and apply 5.0 × 10 6 cells/dose to the expansion phase. In all pts, neither DLT nor MTD were explored. Vaccinations were well tolerated. Pts experienced KSD-101-related adverse events were injection site reactions (grade 1, 90.9%), fever (grade ≤ 2, 72.7%), lymphadenopathy (grade 1, 54.5%) and lymphocythemia (grade 1, 9.1%). The data cutoff was August 14, 2024 and the median follow-up was 54.1 weeks (range, 5.9-71.1 weeks). Two hemophagocytic lymphohistiocytosis pts discontinued from the study due to rapid early-stage disease progression and subsequently received alternative therapeutic interventions. The best ORR was 88.9% (8/9), with all pts achieving complete remission (CR). The DCR was 100% (9/9), with one pt demonstrating stable disease following vaccination. After vaccinations, we found that the peak proportion of EBV-specific T cells in CD3 + CD8 + cells (average, 4.21%) was significantly increased ( p < 0.05) compared to baseline (average, 0.61%) and the peak number of immune cells also increased, such as activated T cells ( p < 0.05, average increased to 2.61-fold), NK cells ( p < 0.01, average increased to 1.77-fold) and CD8 + T cells ( p < 0.05, average increased to 2.02-fold). We also found that the valley number of T-regs significantly reduced ( p < 0.01, average reduced to 58.14%). Conclusions: AS of now, KSD-101 has demonstrated good safety and efficacy and could activate immune system. Our study highlights its potential as a promising therapeutic agent for the treatment of EBV-LPDs. Larger prospective studies and a longer follow-up period is needed to be conducted. Clinical trial information: NCT05635591 .
BibTeX
@article{li2025dendritic,
  author = {Chunrui Li and Di Wang and Atsuhiko Hasegawa and Huining Liu and Peiling Zhang and Yuhan Bao and Ning An and Mei Huang and Yi Xiao and Donghua Zhang and Miao Zheng and Wei Huang and Lijun Jiang},
  title = {{Dendritic cell–based vaccines (KSD-101) against EBV-associated lymphoproliferative diseases: Results from an ongoing phase I clinical study.}},
  journal = {Journal of Clinical Oncology},
  year = {2025},
  doi = {10.1200/jco.2025.43.16\_suppl.e14515},
}

Loading related content...

Figure